Skip to main content
SpringerLink
Log in

Drug-Induced Liver Injury in Humans: The Case of Ximelagatran

  • Chapter
  • First Online:
Book cover Adverse Drug Reactions

Part of the book series: Handbook of Experimental Pharmacology ((HEP,volume 196))

Abstract

Ximelagatran was the first orally available direct thrombin inhibitor under clinical development that also reached the market. Ximelagatran was tested in an extensive clinical programme. Short-term use (<12 days) in humans including the phase III clinical trials did not indicate any hepatotoxic potential. Increased hepatic enzyme levels were first observed at a higher frequency when evaluating the long-term (>35 days) use of ximelagatran (incidence of >3× upper limit of normal (ULN) plasma ALT was 7.9%). The frequency of elevated total bilirubin levels was similar in the ximelagatran and the comparator groups. However, the combination of ALT > 3×ULN and total bilirubin >2×ULN was 0.5% among patients treated with ximelagatran and 0.1% among patients in the comparator group. Symptoms such as fever and rash potentially indicating hypersensitivity (immunologic type of reaction) were low and did not differ between ximelagatran and the comparators. The withdrawal of ximelagatran from the market and termination of the ximelagatran development program was triggered by safety data from a 35-day study, indicating that severe hepatic injury in a patient could develop after exposure to the drug has been completed and that regular liver function monitoring may not mitigate the possible risk of severe hepatic injury. As for many drugs causing liver injury, the standard preclinical toxicological studies provided no indication that ximelagatran affected hepatic functions. In addition, extensive investigations using human-based in vitro models have not been able to define mechanisms explaining the pattern of hepatic injury observed in long-term clinical trials. A pharmacogenomic study provided evidence that the ALT increases were associated with major histocompatibility complex (MHC) alleles DRB1’07 and DQA1*02 suggesting a possible immunogenic pathogenesis. This example provides important clues to the mechanism of idiosyncratic drug-induced liver toxicity.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 299.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Agnelli G, Eriksson BI, Cohen AT, Bergqvist D, Dahl OE, Lassen MR, Mouret P, Rosencher N, Andersson M, Bylock A, Jensen E, Boberg B (2009) On behalf of the EXTEND Study Group. Submitted for publication

    Google Scholar 

  • Ansell J, Hirsch J, Dahlen J, Bussey H, Anderson D, Poller L, Jacobson A, Deykin D, Matchar D (2001) Managing oral anticoagulant therapy. Chest 119(Suppl 1):22S-38S

    Google Scholar 

  • Berlin M, Fogdell-Hahn A, Olerup O, Eklund A, Grunewald J (1997) HLA-DR predicts the prognosis in Scandinavian patients with pulmonary sarcoidosis. Am J Respir Crit Care Med 156:1601-1605

    PubMed  CAS  Google Scholar 

  • Bredberg E, Andersson TB, Frison L, Thuresson A, Johansson S, Eriksson-Lepkowska M, Larsson M, Eriksson UG (2003) Ximelagatran, an oral direct thrombin inhibitor, has a low potential for cytochrome P450-mediated drug-drug interactions. Clin Pharmacokinet 42:765-777

    Article  PubMed  CAS  Google Scholar 

  • Clement B, Lopian K (2003) Characterization of in vitro biotransformation of new, orally active, direct thrombin inhibitor ximelagatran, an amidoxime and ester prodrug. Drug Met Disp 31:645-651

    Article  CAS  Google Scholar 

  • De Groot AS (2006) Immunomics: discovering new targets for vaccines and therapeutics. Drug Discov Today 11:203-209

    Article  PubMed  Google Scholar 

  • Edgar AD, Tomkiewicz C, Costet P, Legendre C, Aggerbeck M, Bouguet J, Staels B, Guyomard C, Pineau T, Barouki R (1998) Fenofibrate modifies transaminase gene expression via a peroxisome proliferator activated receptor alpha-dependent pathway. Toxicol Lett 98:13-23

    Article  PubMed  CAS  Google Scholar 

  • Eriksson BI, Agnelli G, Cohen AT, Dahl OE, Mouret P, Rosencher N, Eskilson C, Nylander I, Frison L, Ögren M (2003a) Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. The METHRO III study. Thromb Haemost 89:288-296

    PubMed  CAS  Google Scholar 

  • Eriksson BI, Agnelli G, Cohen AT, Dahl OE, Lassen MR, Mouret P, Rosencher N, Kälebo P, Panfilov S, Eskilson C, Andersson M (2003b) The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study. Thromb Haemost 1:2490-2496

    Article  CAS  Google Scholar 

  • Eriksson UG, Bredberg U, Hoffmann KJ, Thuresson A, Gabrielsson M, Ericsson H, Ahnoff M, Gislén K, Fager G, Gustafsson D (2003c) Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans. Drug Met Disp 31:294-305

    Article  CAS  Google Scholar 

  • Executive Steering committee on behalf of the SPORIF III Investigators (2003) Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 362:1691-1698

    Article  Google Scholar 

  • Francis CW, Davidson BL, Berkowitz SD, Lotke PA, Ginsberg JS, Lieberman JR, Webster AK, Whipple JP, Peters GR, Clifford W, Colwell CW Jr (2002) Ximelagatran versus Warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized double-blind trial. Ann Intern Med 137:648-655

    Google Scholar 

  • Francis CW, Berkowitz SD, Comp PC, Lieberman JR, Ginsberg JS, Guy Paiement G, Peters GR (2003) Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. N Engl J Med 349:1703-1712

    Article  PubMed  CAS  Google Scholar 

  • Gibert M, Sanchez-Mazas A (2003) Geographic patterns of functional categories of HLA-DRB1 alleles: a new approach to analyse associations between HLA-DRB1 and disease. Eur J Immunogenet 30:361-374

    Article  PubMed  CAS  Google Scholar 

  • Gomez-Lechon MJ, Donato MT, Castell JV, Jover R (2003) Human hepatocytes as a tool for studying toxicity and drug metabolism. Curr Drug Metab 4:292-312

    Article  PubMed  CAS  Google Scholar 

  • Hirsch J, Dahlen J, Anderson DR, Poller L, Bussey H, Ansell J, Deykin D (2001) Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 119(Suppl):8S-21S

    Google Scholar 

  • Kenne K, Skanberg I, Glinghammar B, Berson B, Pessayre D, Flinois J-P, Beaune P, Edebert I, Diaz Pohl C, Carlsson T, Andersson TB (2008) Prediction of drug induced liver injury in humans by using in vitro methods: the case of ximelagatran. Toxicol In Vitro 22:730-746

    Article  PubMed  CAS  Google Scholar 

  • Kindmark A, Jawaid A, Harbron CG, Barratt BJ, Bengtsson OF, Andersson TB, Carlsson S, Cederbrant KE, Gibson NJ, Armstrong M, Lagerström-Fermér ME, Dellsén A, Brown EM, Thornton M, Dukes C, Jenkins SC, Firth MA, Harrod GO, Pinel THE, Billing-Clason SM, Cardon LR, March RE (2008) Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenom J 8:186-195

    Google Scholar 

  • Lee WM (2003) Drug-induced hepatotoxicity. N Engl J Med 349:474-485

    Google Scholar 

  • Lee WM, Larrey D, Olsson R, Lewis JH, Keisu M, Auclert L, Sheth S (2005) Hepatic findings in long-term clinical trials of ximelagatran. Drug Saf 28:351-370

    Article  PubMed  CAS  Google Scholar 

  • Lewis JH, Larrey D, Olsson R, Lee WM, Frison L, Keisu M (2008) Utility of the Roussel Uclaf Causality Assessment Method (RUCAM) to analyze the hepatic findings in a clinical trial program: evaluation of ximelagatran. Int J Clin Pharmacol Ther 46: 327-329

    Google Scholar 

  • Navarro VJ, Senior JR (2006) Drug-related hepatotoxicity. New Eng J Med 354:731-739

    Article  PubMed  CAS  Google Scholar 

  • Park BK, Kitteringham NR, Maggs JL, Pirmohamed M, Williams DP (2005) The role of metabolic activation in drug-induced hepatotoxicity. Ann Rev Pharmacol Toxicol 45:177-202

    Article  CAS  Google Scholar 

  • Petersen P, Grind M, Adler J et al (2003) Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose guiding tolerability and safety study. J Am Coll Cardiol 41:1445-1451

    Google Scholar 

  • Pichler WJ (2002) Pharmacological interaction of drugs with antigen-specific immune receptors: the p-i concept. Curr Opin Allergy Clin Immunol 2:301-305

    Article  PubMed  Google Scholar 

  • Repa JJ, Mangelsdorf DJ (2000) The role of orphan nuclear receptors in the regulation of cholesterol homeostasis. Ann Rev Cell Dev Biol 16:459-481

    Article  CAS  Google Scholar 

  • Schulman S, Wåhlander K, Lundström T, Billing Clason S, Eriksson H for the THRIVE III Investigators (2003) Secondary prevention of venous thromboembolism with the oral direct thrombin tnhibitor ximelagatran. N Engl J Med 349:1713-1721

    Google Scholar 

  • SPORTIF Executive Steering Committee for the SPORTIF V Investigators (2005) Ximelagatran vs Warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. A randomized trial. JAMA 293:690-698

    Google Scholar 

  • Wallentin L, Wilcox RG, Weaver WD, Emanuelsson H, Goodwin A, Nyström P, Bylock A (2003) Oral ximelagatarn for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet 362:789-797

    Article  PubMed  CAS  Google Scholar 

  • Wang H, LeCluyse EL (2003) Role of orphan nuclear receptors in the regulation of drug-metabolising enzymes. Clin Pharmacokin 42:1331-1357

    Article  CAS  Google Scholar 

  • Wolzt M, Wollbratt M, Svensson M, Wåhlander K, Grind M, Eriksson UG (2003) Consistent pharmacokinetics of the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation and in healthy subjects. Eur J Clin Pharmacol 59:537-543

    Article  PubMed  CAS  Google Scholar 

  • Wolzt M, Sarich TS, Eriksson UG (2005) Pharmacokinetics and pharmacodynamics of ximelagatran. Sem Vasc Med 5:245-253

    Article  Google Scholar 

  • Fiessinger JN, Huisman MV, Davidson BL, Bounameaux H, Francis CW, Eriksson H, Lundström T, Berkowitz SD, Nyström P, Thorsén M, Ginsberg JS (2005) Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis. A randomized trial. JAMA 293:681-689

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. AstraZeneca, R&D Mölndal, S 431 83 Mölndal, Sweden and Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden

    T. B. Andersson

Authors
  1. M. Keisu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T. B. Andersson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T. B. Andersson .

Editor information

Editors and Affiliations

  1. Faculty of Pharmacy, University of Toronto, Toronto, Canada, M5S 2S2

    Jack Uetrecht (Professor of Pharmacy and Medicine, Canada Research Chair in Adverse Drug Reactions) (Professor of Pharmacy and Medicine, Canada Research Chair in Adverse Drug Reactions)

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Keisu, M., Andersson, T.B. (2010). Drug-Induced Liver Injury in Humans: The Case of Ximelagatran. In: Uetrecht, J. (eds) Adverse Drug Reactions. Handbook of Experimental Pharmacology, vol 196. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-00663-0_13

Download citation

Publish with us

Policies and ethics

Search

Navigation